The European Medicines Agency (EMA) has granted a marketing authorization to Novartis Europharm for Fabhalta (iptacopan) for treating adults with paroxysmal nocturnal hemoglobinuria (PNH) who have hemolytic anemia.
https://www.medscape.com/viewarticle/eu-backs-first-oral-monotherapy-adults-pnh-2024a10005ft?src=
No hay comentarios:
Publicar un comentario